Compass Therapeutics, Inc. CMPX 深 沪
已收盘 08-14 16:00:00 美东时间
2.25
-0.010
-0.44%
华盛通- 最 高2.30
- 今 开2.30
- 成交量 136.21万股
- 最 低 2.23
- 昨 收 2.26
- 总市值 4.05亿
- 52周最高 6.88
- 市盈率 静 --
- 换手率 0.76%
- 52周最低 1.61
- 委 比 30.31%
- 总股本 1.80亿
- 历史最高 6.88
- 量 比 0.30
- 振 幅 3.10%
- 历史最低 0.765
- 每 手 1
- 风险率 1.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6
Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight and raises the price target from $4 to $6.
08-08 00:58
Compass Therapeutics Q2 EPS $(0.13) Misses $(0.11) Estimate
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 7.14 percent increase over losses of $(0.14) per share from the same period last year.
08-06 19:56
Compass Therapeutics Abstract Accepted For Oral Presentation At Upcoming European Society For Medical Oncology Congress
Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled "A randomized trial of paclitaxel ± tovecimig in previously treated pat...
07-17 22:47
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Compass Therapeutics announced that its abstract on a randomized trial of paclitaxel ± tovecimig in advanced biliary tract cancer has been accepted for an oral presentation at the ESMO Congress 2026 in Madrid. The presentation will discuss results from the Phase 2/3 COMPANION-002 trial, focusing on tovecimig, a DLL4 x VEGF-A bispecific antibody, in combination with paclitaxel. The session will be held on October 24, 2026, from 10:15am to 11:45am ...
07-17 14:42
Compass Showcases Promising Tovecimig Data, Eyes Commercialization
Compass Therapeutics ( ($CMPX) ) has shared an announcement. On July 1, 2026, C...
07-02 05:30
Compass Therapeutics Adopts Second Amended and Restated Bylaws
Compass Therapeutics ( ($CMPX) ) has provided an update. On June 22, 2026, Comp...
06-23 18:50
Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight
Compass Therapeutics ( ($CMPX) ) just unveiled an announcement. On June 10, 202...
06-12 05:24
Compass Therapeutics' CTX-8371 Dual PD-1/PD-L1 Bispecific Shows Durable Monotherapy Responses In Advanced Checkpoint-Resistant Cancers With Favorable Safety Profile
CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies
05-22 05:08
